Between 2004 and 2006, three anti-VEGF drugs (Pegaptanib, ranibizumab, and bevacizumab) with different sites of action, formulations, binding affinities, and biologic activities were introduced for the treatment of wet AMD. This evidence concerns the gene VEGFA and wet macular degeneration.